CONTROL ANGIOGENESIS BY REGULATING PHOSPHORYLATION OF SERYL-tRNA SYNTHETASE (SerRS)
AssigneeThe Scripps Research Institute
InventorsXiang-Lei Yang, Yi Shi, Ze Liu
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for modulating angiogenesis, and reducing tumor progression by regulating phoosprylation, of seryl-tRNA synthase (SerRS). Also disclosed are related compositions and methods for treating diseases such as cancer.
Claims39
A method of reducing tumor progression in a subject, comprising:
- administering a composition comprising a mutant seryl-tRNA synthetase (SerRS) protein to a subject in need, wherein the mutant SerRS protein is a phosphorylation-deficient mutant SerRS protein,
- whereby tumor progression is reduced in the subject.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A mutant seryl-tRNA synthetase (SerRS) protein, wherein the mutant SerRS protein is phosphorylation-deficient, or is deficiency in repressing VEGF transcription as compared to the corresponding wildtype SerRS protein, or is effective in stimulating VEGF transcription, wherein the mutant SerRS protein comprises an amino acid substitution or an amino acid deletion at one or more of residues T22, X79, S86, X101, X142, S217, S241, S255, S258, S262, S368, S394, S396, T214, T501, X220, Y248, and Y263 relative to the corresponding wildtype SerRS protein, wherein X is serine, tyrosine or threonine.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-67. (canceled)
Dependencies are inferred from the claim text.